PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3924561

Sleep and epilepsy.

J Montplaisir·M Laverdière·J M Saint-Hilaire
View original source ↗Export metadata ↓

Abstract

One of the main advantages of long-term recording of epileptics is the possibility to monitor these patients during natural sleep. In this chapter, we first describe the reciprocal influence of sleep and epilepsy. On the one hand, sleep and circadian fluctuation of the state of vigilance have a marked influence on the occurrence of generalized and partial seizures as well as on the frequency, morphology and distribution of interictal epileptic discharges. On the other hand, a wide range of sleep disturbances has been documented in epileptics and there is some evidence that sleep disturbance and epilepsy may aggravate and perpetuate one another. Long-term EEG monitoring during sleep is of major importance when investigating epileptics with nocturnal attacks to determine whether these nocturnal episodes represent an ictal manifestation or an independent non-epileptic sleep disorder. In special forms of epilepsy, sleep recording is not only useful but necessary for the diagnosis. Various activation procedures are carried out on patients in whom there is diagnostic uncertainty regarding the presence or the type of epilepsy. Some of these procedures employ sleep: namely sedated sleep, sleep after sleep deprivation and all-night sleep recording. The diagnostic value and the indications of these activation studies are reviewed.

Explore related subjects

BrainCircadian RhythmElectroencephalographyEpilepsies, PartialEpilepsyEpilepsy, Tonic-ClonicHumansLong-Term CareMonitoring, PhysiologicSleepSleep DeprivationSleep Wake DisordersSleep, REMJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Montplaisir, M Laverdière, J M Saint-Hilaire. 1985. Sleep and epilepsy.. https://pubmed.ncbi.nlm.nih.gov/3924561/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

A MAGIBU-based model for pediatric and juvenile CNS tumors: an in-house epigenetic decision-support framework compared with online DNA methylation classifiers.

Background: DNA methylation profiling is a tool that provides key support for central nervous system (CNS) tumor classification. However, diagnostically ambiguous pediatric cases may result in discordant outputs across classifiers. We developed MAGIBU, a cross-platform, projection-based framework that embeds individual methylomes into a fixed CNS reference landscape, ranking diagnostic entities by local epigenetic proximity to support clinician-led integrative diagnosis. Methods: As a proof-of-concept, we evaluated MAGIBU in eight morphologically challenging pediatric/juvenile CNS tumors with unresolved diagnoses after institutional and central pathology review. To establish a benchmark in the absence of a definitive histopathological ground truth, a consensus epigenetic reference was defined a priori for cases showing concordant results between the Heidelberg CNS Tumor Methylation Classifier and Methylscape Analysis. Comparisons were also performed with Epigenomic Digital Pathology (EpiDiP). To validate MAGIBU beyond this discovery cohort, performance was assessed at the family level across the CNS methylation spectrum (n = 678, 28 methylation families), on non-array platforms (whole-genome bisulfite sequencing and Oxford Nanopore), and in a focused analysis of the low-grade glioma and diffuse midline glioma compartment across four independent cohorts (n = 670). Results: In the discovery cohort, MAGIBU achieved high concordance with the consensus reference (Cohen's κ = 0.855), outperforming EpiDiP (κ = 0.278), which frequently placed low-grade tumors in proximity to higher-grade reference regions. Conclusions: MAGIBU provides a stable, quantitative differential diagnosis framework that mitigates the limitations of rigid categorical assignments. By leveraging a distance-based proximity metric, it offers a transparent decision-support tool that integrates effectively with clinical, radiological, and molecular data. While performance is inherently dependent on reference atlas composition, MAGIBU represents a robust complementary approach for the diagnostic workup of ambiguous CNS tumors.

Brain↗
PubMed2021

1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans.

Low-frequency 1q21.1 distal deletion and duplication copy number variant (CNV) carriers are predisposed to multiple neurodevelopmental disorders, including schizophrenia, autism and intellectual disability. Human carriers display a high prevalence of micro- and macrocephaly in deletion and duplication carriers, respectively. The underlying brain structural diversity remains largely unknown. We systematically called CNVs in 38 cohorts from the large-scale ENIGMA-CNV collaboration and the UK Biobank and identified 28 1q21.1 distal deletion and 22 duplication carriers and 37,088 non-carriers (48% male) derived from 15 distinct magnetic resonance imaging scanner sites. With standardized methods, we compared subcortical and cortical brain measures (all) and cognitive performance (UK Biobank only) between carrier groups also testing for mediation of brain structure on cognition. We identified positive dosage effects of copy number on intracranial volume (ICV) and total cortical surface area, with the largest effects in frontal and cingulate cortices, and negative dosage effects on caudate and hippocampal volumes. The carriers displayed distinct cognitive deficit profiles in cognitive tasks from the UK Biobank with intermediate decreases in duplication carriers and somewhat larger in deletion carriers-the latter potentially mediated by ICV or cortical surface area. These results shed light on pathobiological mechanisms of neurodevelopmental disorders, by demonstrating gene dose effect on specific brain structures and effect on cognitive function.

Brain↗